Sunday, October 4, 2026

Silver Bearish Momentum: 6.46% Down Since The Last Session

ViaNews Editorial Team

January 8, 2021

Silver Bearish Momentum: 6.46% Down Since The Last Session

Silver is currently on bearish momentum. At 18:05 EST on Friday, 8 January, Silver is at $25.50 and 6.46% down since the last session's close.

Silver Range

Silver is 6.388% down from its last session low of $27.24 and 6.628% down from its last session high of $27.31.

Silver is 8.29% down from its last three sessions higher value of $27.81 and is 6.39% down from its last three sessions lower value of $27.24.

Silver is 8.29% down from its last seven sessions higher value of $27.81 and is 3.21% down from its last seven sessions lower value of $26.35.

Silver is 8.29% down from its last month's higher value of $27.81 and is 6.52% up from its last month's lower value of $23.94.

Volatility

Silver's last day, last week, and last month's average volatility was 1.19%, 1.80%, and 1.30%, respectively.

Silver's last day, last week, and last month's high and low average amplitude percentage was 0.26%, 0.62%, and 0.79%, respectively.

Last news about Silver

Silver state schools credit union celebrates 70 years of excellent member service. According to Business Insider on Tuesday, 5 January, "On January 2, 1951, Harold McKay, a Clark County educator in the 1940's, along with six other educators, founded what is now known as Silver State Schools Credit Union. ", "Credit unionsare essential for the community as a whole and the members we serve," says Scott A. Arkills, President and CEO, Silver State Schools Credit Union."Our valued members are the heart of everything we do."

Pan american silver provides release dates for 2021 guidance, 2020 preliminary production and full year 2020 audited results. According to Business Insider on Wednesday, 6 January, "VANCOUVER, BC, Jan. 5, 2021 /CNW/ - Pan American Silver Corp.(NASDAQ: PAAS) (TSX: PAAS) ("Pan American") will announce 2021 guidance and preliminary 2020 production results on Tuesday, January 19, 2021, followed by a conference call and webcast to be held the same day."

Albemarle plans to double lithium carbonate production at silver peak site - quick facts. According to Business Insider on Thursday, 7 January, "Albemarle Corporation (ALB) said it will expand capacity at the company's lithium production facility in Silver Peak, Nev. "

Summa silver to commence trading on the TSX venture exchange under the ticker symbol "ssvr". According to Business Insider on Friday, 8 January, "Follow Summa Silver on Twitter: @summasilver LinkedIn: https://www.linkedin.com/company/summa-silver-corp/", "VANCOUVER, BC, Jan. 7, 2021 /CNW/ - Summa Silver Corp. (TSXV: SSVR) (OTCQB: SSVRF) (Frankfurt: 48X) ("Summa Silver" or the "Company") is pleased to announce that it has received final approval for listing on the TSX Venture Exchange ("TSXV"). "

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com